In vitro activity of tigecycline against extended-spectrum ß-lactamase-producing Enterobacteriaceae and MRSA clinical isolates from Mexico: a multicentric study.
Diagn Microbiol Infect Dis
; 70(2): 270-3, 2011 Jun.
Article
en En
| MEDLINE
| ID: mdl-21596226
ABSTRACT
Extended-spectrum ß-lactamase (ESBL)-producing Enterobacteriaceae and methicillin resistant Staphylococcus aureus (MRSA) are important nosocomial pathogens. This study reports the in vitro activity of tigecycline against 573 and 482 ESBL-producing Enterobacteriaceae and MRSA isolates, respectively. More than 94% of all tested isolates were susceptible to tigecycline; MIC(90) found was 0.25 to 2 mg/L for ESBL-producing Enterobacteriaceae and was 0.125 mg/L for MRSA. Tigecycline demonstrated excellent in vitro activity against a wide spectrum of nosocomial pathogens.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Infecciones Estafilocócicas
/
Beta-Lactamasas
/
Enterobacteriaceae
/
Infecciones por Enterobacteriaceae
/
Staphylococcus aureus Resistente a Meticilina
/
Minociclina
/
Antibacterianos
Tipo de estudio:
Clinical_trials
Límite:
Adolescent
/
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
País/Región como asunto:
Mexico
Idioma:
En
Revista:
Diagn Microbiol Infect Dis
Año:
2011
Tipo del documento:
Article